Search hospitals > North Carolina > Winston Salem
Novant Health Forsyth Medical Center
Claim this profileWinston Salem, North Carolina 27103
Global Leader in Breast Cancer
Global Leader in Cancer
Conducts research for Stroke
Conducts research for Coronary Artery Disease
Conducts research for Lung Cancer
177 reported clinical trials
18 medical researchers
Summary
Novant Health Forsyth Medical Center is a medical facility located in Winston Salem, North Carolina. This center is recognized for care of Breast Cancer, Cancer, Stroke, Coronary Artery Disease, Lung Cancer and other specialties. Novant Health Forsyth Medical Center is involved with conducting 177 clinical trials across 264 conditions. There are 18 research doctors associated with this hospital, such as Judith O. Hopkins, James Dugan, Demetria I. Jacks, and Volker W. Stieber.Area of expertise
1Breast Cancer
Global LeaderER positive
HER2 negative
HER2 positive
2Cancer
Global LeaderStage IV
HER2 positive
Stage II
Top PIs
Judith O. HopkinsNovant Health Forsyth Medical Center1 year of reported clinical research
Studies Breast Cancer
Studies Cancer
9 reported clinical trials
35 drugs studied
James DuganNovant Health3 years of reported clinical research
Studies Leukemia
Studies Acute Myeloid Leukemia
6 reported clinical trials
7 drugs studied
Demetria I. JacksNovant Health Cancer Institute1 year of reported clinical research
Studies Oropharyngeal Cancer
Studies Cancer
4 reported clinical trials
7 drugs studied
Volker W. StieberNovant Health Forsyth Medical Center5 years of reported clinical research
Studies Glioblastoma
Studies Brain Metastasis
4 reported clinical trials
12 drugs studied
Clinical Trials running at Novant Health Forsyth Medical Center
Breast Cancer
Lung Cancer
Acute Myeloid Leukemia
Non-Small Cell Lung Cancer
Prostate Cancer
Leukemia
Cancer
Stroke
Lymphoma
Lung Carcinoma
Pembrolizumab
for Triple-Negative Breast Cancer
The phase III trial compares the effect of pembrolizumab to observation for the treatment of patients with early-stage triple-negative breast cancer who achieved a pathologic complete response after preoperative chemotherapy in combination with pembrolizumab. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. This trial may help researchers determine if observation will result in the same risk of cancer coming back as pembrolizumab after surgery in triple-negative breast cancer patients who achieve pathologic complete response after preoperative chemotherapy with pembrolizumab.
Recruiting2 awards Phase 319 criteria
Chemotherapy + Hormone Therapy
for Breast Cancer
This trial is testing if adding additional cancer-fighting drugs to treatments that stop certain body functions is better than just using the treatments that stop those functions alone. It targets younger women with early-stage breast cancer who have a higher risk of dying from the disease. The treatment works by stopping certain body functions and using drugs to kill cancer cells.
Recruiting2 awards Phase 319 criteria
Hormone Therapy with or without Radiation
for Breast Cancer
This Phase III Trial evaluates whether breast conservation surgery and endocrine therapy results in a non-inferior rate of invasive or non-invasive ipsilateral breast tumor recurrence (IBTR) compared to breast conservation with breast radiation and endocrine therapy.
Recruiting2 awards Phase 313 criteria
Similar Hospitals nearby
Select from list below to view details
Frequently asked questions
What kind of research happens at Novant Health Forsyth Medical Center?
Novant Health Forsyth Medical Center is a medical facility located in Winston Salem, North Carolina. This center is recognized for care of Breast Cancer, Cancer, Stroke, Coronary Artery Disease, Lung Cancer and other specialties. Novant Health Forsyth Medical Center is involved with conducting 177 clinical trials across 264 conditions. There are 18 research doctors associated with this hospital, such as Judith O. Hopkins, James Dugan, Demetria I. Jacks, and Volker W. Stieber.